Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Dermatology

Dermatology

Evaluate

Thumbnail
August 01, 2023

US FDA approval and panel tracker: July 2023

July 20, 2023

Spotlight – scratching the surface of the urticaria pipeline

Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.

Article image
Vantage logo
July 07, 2023

Coloplast hooks fish skin tech group for $1.2bn

Article image
Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Article image
Vantage logo
April 05, 2023

Benevolent AI’s dermatology Trk disappoints

Article image
Vantage logo
April 03, 2023

Spotlight – following Humira in hidradenitis suppurativa

Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.

Article image
Vantage logo
March 31, 2023

Go or no go? Seagen's Padcev eyes FDA approval

Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.

Article image
Vantage logo
March 20, 2023

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

But Humira remains the one to beat.

Article image
Vantage logo
March 20, 2023

AAD 2023 – Takeda outdoes Bristol’s Sotyktu

TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

Article image
Vantage logo
March 07, 2023

Investors await details on Protagonist’s oral interleukin win

Article image
Vantage logo
December 13, 2022

Takeda Tyks the deal-making box

For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up